iRhythm Technologies, Inc. announced that the company has successfully launched the initial phases of its previously disclosed manufacturing automation plans, marking a significant corporate milestone expected to set the stage for future growth and innovation while also yielding substantial cost savings. In this initial phase, iRhythm has implemented a cutting-edge autohandler machine to automate the testing of printed circuit board assembly (PCBA) components of the recently- launched Zio monitor. This advanced technology automates the functional testing of PCBAs, handles their movement to and from test fixtures, and efficiently separates passed and failed units, streamlining the manufacturing process and enhancing overall efficiency.

Zio monitor was previously assembled and tested manually; the introduction of manufacturing automation enhances iRhythm's scalability for continued expansion in both the U.S. and international markets. Additionally, as the company anticipates that the new Zio monitor will serve as the foundational hardware platform for future technology iterations - including the next generation mobile cardiac telemetry (MCT) product - automation will be crucial in keeping pace with the projected global demand for its Zio ECG monitoring products. The company anticipates that all phases of planned manufacturing improvements will enable capacity production of up to 10 million units annually.